DE

461.1

+0.15%↑

CTAS

209.19

+0.45%↑

CPRT

60.57

+1.25%↑

CSX

28.05

+0.65%↑

PAYX

146.47

+1.65%↑

DE

461.1

+0.15%↑

CTAS

209.19

+0.45%↑

CPRT

60.57

+1.25%↑

CSX

28.05

+0.65%↑

PAYX

146.47

+1.65%↑

DE

461.1

+0.15%↑

CTAS

209.19

+0.45%↑

CPRT

60.57

+1.25%↑

CSX

28.05

+0.65%↑

PAYX

146.47

+1.65%↑

DE

461.1

+0.15%↑

CTAS

209.19

+0.45%↑

CPRT

60.57

+1.25%↑

CSX

28.05

+0.65%↑

PAYX

146.47

+1.65%↑

DE

461.1

+0.15%↑

CTAS

209.19

+0.45%↑

CPRT

60.57

+1.25%↑

CSX

28.05

+0.65%↑

PAYX

146.47

+1.65%↑

Ocugen Inc

Затворен

0.72 2.86

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

0.67

Максимум

0.73

Ключови измерители

By Trading Economics

Приходи

-910K

-14M

Продажби

-372K

764K

EPS

-0.05

Марж на печалбата

-1,816.754

Служители

95

EBITDA

-603K

-13M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+839.44% upside

Пазарни показатели

By TradingEconomics

Пазарна капитализация

39M

215M

Предишно отваряне

-2.14

Предишно затваряне

0.72

Техническа оценка

By Trading Central

Увереност

Very Strong Bullish Evidence

Ocugen Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

29.04.2025 г., 23:53 ч. UTC

Горещи акции

Stocks to Watch: Starbucks, Snap, Super Micro Computer, Seagate Technology

29.04.2025 г., 23:06 ч. UTC

Печалби

Prudential PLC 1Q New Business Profit Increases by 12%

29.04.2025 г., 23:00 ч. UTC

Печалби

America Movil's Posts Rise in 1Q Profit, Revenue

30.04.2025 г., 00:00 ч. UTC

Топ новини

Buffett's 'Woodstock for Capitalists' Draws Admirers From Around the Globe -- WSJ

29.04.2025 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Rise as Fears About U.S. Tariffs Ebb -- Market Talk

29.04.2025 г., 23:43 ч. UTC

Пазарно говорене

Gold Consolidates; Signs of Easing in U.S. Tariffs' Impact May Weigh -- Market Talk

29.04.2025 г., 23:41 ч. UTC

Печалби

China Minsheng Banking 1Q Net Interest Income CNY24.87B Vs. CNY24.26B>1988.HK

29.04.2025 г., 23:41 ч. UTC

Печалби

China Minsheng Banking 1Q Operating Income CNY36.81B Vs. CNY34.27B>1988.HK

29.04.2025 г., 23:41 ч. UTC

Печалби

China Minsheng Banking 1Q Net CNY12.74B Vs. Net CNY13.45B >1988.HK

29.04.2025 г., 23:24 ч. UTC

Печалби

China Vanke 1Q Rev CNY37.99B Vs. CNY61.59B >000002.SZ

29.04.2025 г., 23:24 ч. UTC

Печалби

China Vanke: Increase in Investment Losses Also Hurt Results >000002.SZ

29.04.2025 г., 23:24 ч. UTC

Печалби

China Vanke 1Q Loss CNY6.25B Vs. Loss CNY361.97M >000002.SZ

29.04.2025 г., 23:24 ч. UTC

Печалби

China Vanke: Singificant Decline in Property Sales Weighed on Results >000002.SZ

29.04.2025 г., 23:24 ч. UTC

Печалби

China Vanke 1Q Loss Widened Significantly >000002.SZ

29.04.2025 г., 23:15 ч. UTC

Топ новини

UPS to Cut 20,000 Jobs After Amazon Breakup -- 2nd Update

29.04.2025 г., 23:14 ч. UTC

Печалби

China Eastern Airlines 1Q Loss CNY995.0M Vs. Loss CNY803.0M >0670.HK

29.04.2025 г., 23:14 ч. UTC

Печалби

China Eastern Airlines: Increased Competition in the Aviation Market Hurt Results >0670.HK

29.04.2025 г., 23:14 ч. UTC

Печалби

China Eastern Airlines 1Q Rev CNY33.41B Vs. CNY33.19B >0670.HK

29.04.2025 г., 23:14 ч. UTC

Печалби

China Eastern Airlines 1Q Loss Widened >0670.HK

29.04.2025 г., 23:11 ч. UTC

Печалби

China Southern Airlines Swung to Loss in 1Q>1055.HK

29.04.2025 г., 23:11 ч. UTC

Печалби

China Southern Airlines 1Q Rev CNY43.41B Vs. CNY44.60B >1055.HK

29.04.2025 г., 23:11 ч. UTC

Печалби

China Southern Airlines: Shift in Traveler Demographics, Competition From High-Speed Rail Networks Also Hurt Results >1055.HK

29.04.2025 г., 23:11 ч. UTC

Печалби

China Southern Airlines 1Q Loss CNY747.0M Vs. Net CNY756.0M >1055.HK

29.04.2025 г., 23:11 ч. UTC

Печалби

China Southern Airlines: CNY Depreciation, Global Supply Chain Constraints Among Factors Weighing on Results >1055.HK

29.04.2025 г., 23:07 ч. UTC

Печалби

Air China 1Q Rev CNY40.02B Vs. CNY40.07B >0753.HK

29.04.2025 г., 23:07 ч. UTC

Печалби

Air China 1Q Losses Widened>0753.HK

29.04.2025 г., 23:07 ч. UTC

Печалби

Air China 1Q Loss CNY2.04B Vs. Loss CNY1.67B >0753.HK

29.04.2025 г., 23:02 ч. UTC

Печалби

COSCO SHIPPING Energy Transportation: Weaker Earnings In International Oil Tanker Fleet Business Weighed on Results>1138.HK

29.04.2025 г., 23:02 ч. UTC

Печалби

COSCO SHIPPING Energy Transportation 1Q Net CNY707.70M Vs. Net CNY1.24B >1138.HK

29.04.2025 г., 23:02 ч. UTC

Печалби

COSCO SHIPPING Energy Transportation 1Q Rev CNY5.75B Vs. CNY5.84B >1138.HK

Сравнение с други в отрасъла

Ценова промяна

Ocugen Inc Прогноза

Ценова цел

By TipRanks

839.44% нагоре

12-месечна прогноза

Среден 6.67 USD  839.44%

Висок 8 USD

Нисък 4 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Ocugen Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

3 ratings

3

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

0.7107 / 0.735Подкрепа & съпротива

Краткосрочен план

Very Strong Bullish Evidence

Средносрочен план

Strong Bullish Evidence

Дългосрочен план

No Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.